C26-linked rapamycin analogs as mTOR inhibitors
US12187746B2 · kind B2 · utility
1Cited by
84References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2023 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Apr 14, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.